CL2022001167A1 - Tratamiento de trastornos hepáticos - Google Patents

Tratamiento de trastornos hepáticos

Info

Publication number
CL2022001167A1
CL2022001167A1 CL2022001167A CL2022001167A CL2022001167A1 CL 2022001167 A1 CL2022001167 A1 CL 2022001167A1 CL 2022001167 A CL2022001167 A CL 2022001167A CL 2022001167 A CL2022001167 A CL 2022001167A CL 2022001167 A1 CL2022001167 A1 CL 2022001167A1
Authority
CL
Chile
Prior art keywords
treatment
liver disorders
disorders
manifestations
symptoms
Prior art date
Application number
CL2022001167A
Other languages
English (en)
Spanish (es)
Inventor
Weidong Zhong
Martijn Fenaux
Yujin Wang
Kevin Klucher
Original Assignee
Terns Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Terns Pharmaceuticals Inc filed Critical Terns Pharmaceuticals Inc
Publication of CL2022001167A1 publication Critical patent/CL2022001167A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2022001167A 2019-11-08 2022-05-04 Tratamiento de trastornos hepáticos CL2022001167A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962933277P 2019-11-08 2019-11-08
US202063004403P 2020-04-02 2020-04-02

Publications (1)

Publication Number Publication Date
CL2022001167A1 true CL2022001167A1 (es) 2023-02-10

Family

ID=75849579

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022001167A CL2022001167A1 (es) 2019-11-08 2022-05-04 Tratamiento de trastornos hepáticos

Country Status (11)

Country Link
EP (1) EP4054567A4 (de)
JP (1) JP2023501386A (de)
KR (1) KR20220098168A (de)
CN (1) CN114667142A (de)
AU (1) AU2020380968A1 (de)
BR (1) BR112022008639A2 (de)
CA (1) CA3160445A1 (de)
CL (1) CL2022001167A1 (de)
IL (1) IL292459A (de)
MX (1) MX2022005407A (de)
WO (1) WO2021092474A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3201466A1 (en) 2020-12-14 2022-06-23 Regeneron Pharmaceuticals, Inc. Methods of treating metabolic disorders and cardiovascular disease with inhibin subunit beta e (inhbe) inhibitors
TW202539702A (zh) * 2024-03-08 2025-10-16 大陸商上海拓界生物醫藥科技有限公司 靶向ＩＮＨＢＥ的ＲＮＡｉ劑

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200906823A (en) * 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
US20140187633A1 (en) * 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US11419878B2 (en) * 2016-03-28 2022-08-23 Intercept Pharmaceuticals, Inc. Medicine obtained by combining FXR agonist and ARB
WO2018170173A1 (en) * 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
US20210121493A1 (en) * 2017-07-25 2021-04-29 Cedars-Sinai Medical Center Methods for treating liver diseases
EP3844156A4 (de) * 2018-08-30 2022-06-08 Terns Pharmaceuticals, Inc. Behandlung von lebererkrankungen

Also Published As

Publication number Publication date
CA3160445A1 (en) 2021-05-14
CN114667142A (zh) 2022-06-24
EP4054567A4 (de) 2024-01-10
IL292459A (en) 2022-06-01
MX2022005407A (es) 2022-05-24
JP2023501386A (ja) 2023-01-18
BR112022008639A2 (pt) 2022-07-19
KR20220098168A (ko) 2022-07-11
WO2021092474A1 (en) 2021-05-14
EP4054567A1 (de) 2022-09-14
AU2020380968A1 (en) 2022-05-12

Similar Documents

Publication Publication Date Title
ZA202204929B (en) Rimegepant for cgrp related disorders
CO2020004301A2 (es) Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih
MX2021002305A (es) Tratamiento de trastornos del higado.
PH12017500583B1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
PH12016501457A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
ECSP17073878A (es) Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue
MX385332B (es) Moduladores de ror-gamma.
EA201692487A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
EA201892075A1 (ru) Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей
MX2017001656A (es) Combinaciones de inhibidor de tirosina cinasa de bruton y usos de estas.
CL2019002240A1 (es) Dendrímeros terapéuticos.
MX2021015854A (es) Composiciones y métodos para tratar trastornos del snc.
EA201692268A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
MX2022005563A (es) Ligandos de la pseudoquinasa tyk2.
BR112022009710A2 (pt) Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2
MX2019007892A (es) Compuestos inhibidores de metaloenzimas.
PH12021550671A1 (en) Prodrugs of cgrp antagonists
MX2019007161A (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
CL2022001167A1 (es) Tratamiento de trastornos hepáticos
CR20220071A (es) Composiciones farmacéuticas y métodos para tratar o prevenir la atrofia muscular espinal
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
EA202191115A1 (ru) Новые пиридазины
MX2022006812A (es) Metodos para tratar epoc mediante la administracion de un antagonista de il-33.
MX2022005250A (es) Combinaciones terapeuticas de acalabrutinib y capivasertib para tratar neoplasias malignas de linfocitos b.
CL2023002120A1 (es) Terapia combinada de un inhibidor de alk2 y un inhibidor de jak2